Johnson & Johnson $JNJ is Absher Wealth Management LLC’s 8th Largest Position

Absher Wealth Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 8.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 146,263 shares of the company’s stock after selling 14,344 shares during the period. Johnson & Johnson accounts for about 4.2% of Absher Wealth Management LLC’s holdings, making the stock its 8th largest holding. Absher Wealth Management LLC’s holdings in Johnson & Johnson were worth $35,753,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kellett Wealth Advisors LLC raised its position in Johnson & Johnson by 14.0% in the first quarter. Kellett Wealth Advisors LLC now owns 2,406 shares of the company’s stock valued at $588,000 after purchasing an additional 296 shares during the period. IFC Advisors LLC lifted its position in shares of Johnson & Johnson by 1.8% during the first quarter. IFC Advisors LLC now owns 4,642 shares of the company’s stock worth $1,135,000 after purchasing an additional 83 shares in the last quarter. Vantage Point Financial LLC boosted its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Vantage Point Financial LLC now owns 3,013 shares of the company’s stock valued at $737,000 after purchasing an additional 102 shares during the period. Triglav Investments D.O.O. boosted its stake in shares of Johnson & Johnson by 40.5% in the first quarter. Triglav Investments D.O.O. now owns 113,518 shares of the company’s stock valued at $27,748,000 after purchasing an additional 32,700 shares during the period. Finally, J. Safra Sarasin Holding AG grew its holdings in Johnson & Johnson by 0.6% during the 1st quarter. J. Safra Sarasin Holding AG now owns 481,585 shares of the company’s stock valued at $117,669,000 after purchasing an additional 2,782 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ beat Q2 estimates, with EPS of $2.90 and revenue of $25.31 billion, helped by strong pharmaceutical growth from Darzalex, Tremfya and Spravato. Reuters article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $11.60-$11.75 and revenue of about $100.8 billion-$101.4 billion, signaling management confidence in continued growth. Business Wire article
• Positive Sentiment: Jefferies highlighted Spravato’s strong sales growth as a positive read-through for the broader psychedelic/depression-treatment market, reinforcing the value of J&J’s innovative medicines franchise. Proactive Investors article
• Positive Sentiment: Unusual options activity leaned bullish, with traders buying more JNJ call options than usual, suggesting some expectations for upside after earnings.
• Neutral Sentiment: Johnson & Johnson declared a quarterly dividend of $1.34 per share, underscoring its shareholder-return profile and dividend-king status.
• Neutral Sentiment: Stifel maintained a Hold rating with a $260 price target, reflecting a balanced view after the earnings report. TipRanks article
• Negative Sentiment: Despite the beat-and-raise quarter, the stock slipped because investors appeared underwhelmed relative to elevated expectations and are still weighing MedTech softness and talc-related legal risk. MarketBeat article

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $247.55 on Thursday. The stock has a market capitalization of $595.90 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.42 and a beta of 0.24. Johnson & Johnson has a one year low of $159.80 and a one year high of $269.43. The company’s 50-day simple moving average is $238.64 and its 200-day simple moving average is $234.20. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.02 billion. During the same period in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on JNJ. Raymond James Financial boosted their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Wells Fargo & Company raised their target price on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research note on Wednesday. Weiss Ratings downgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. Finally, Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $261.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.